Baixar PDF

Outros usuários também visualizaram estes artigos

Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression Lucia Vráblová; Hana Klamová; Ivana Skoumalová; Jana Navrátilová; Romana Janská; Jan Grohmann; Milena Holzerová; Edgar Faber;
Hematol Transfus Cell Ther. 2024;46 Supl 6:S171-81
Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel Elvira D. Rodrigues Pereira Velloso; Geórgia A. Padulla; Ana Maria Mósca de Cerqueira; Adriana Martins de Sousa; Alex Freire Sandes; Fabiola Traina; Fernanda Salles Seguro; Frederico Lisboa Nogueira; Grazielly de Fátima Pereira; José Laerte Boechat; Katia Borgia Barbosa Pagnano; Luan Lima Marchi; Luis Felipe Ensina; Mara Giavina-Bianchi; Marcelo Vivolo Aun; Rosana Câmara Agondi; Fabio Pires de Souza Santos; Pedro Giavina-Bianchi;
Hematol Transfus Cell Ther. 2022;44:582-94
Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice Carla Boquimpani; Fernanda Salles Seguro; Gustavo Henrique Romani Magalhães; Ingrid Luise Soares Pinto; Israel Bendit; Jaisson André Pagnoncelli Bortolini; Katia Borgia Barbosa Pagnano; Renato Centrone; Vaneuza Funke;
Hematol Transfus Cell Ther. 2022;44:402-9